Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
INVESTORS
CAREERS
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2026-03-13
Novamab Announces China Phase Ⅱ Clinical Trial Approval for First-in-Class Inhaled IL-4Rα VHH Antibody LQ036 Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD)
More
2019-10-16
Publication of research and development results of industrialized new PD-1 VHH antibody drug expressed by Pichia pastoris
More
2019-10-10
Report on the 29th ERS (European Respiratory Society Annual Conference) Conference of Loki Biology
More
2019-07-27
Don't forget your original intention and move forward courageously -- and Loqi 2019 Mid-Year Summary and Commendation Conference
More
2019-04-11
LQ036, the world's first inhaled VHH antibody drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
2018-10-31
Novamab won the winner of the 2018 "Entrepreneurship in Shanghai" International Innovation and Entrepreneurship Competition
More
Total 55 123456